Life Sciences Research for Lifelong Health

Matthew Sale

Matt grew up in Southampton and studied Biochemistry at the University of Oxford. During his degree he developed an interest in cell signalling and cancer, and in 2009 decided to embark on a PhD in the Cook laboratory. As the first ever male PhD student in the Cook group, Matt was an experiment in his own right. However, this did not deter him and he relished the opportunity to investigate a broad range of topics including acquired resistance to MEK1/2 inhibitors, tumour cell responses to MEK1/2 inhibitor combinations with other targeted agents and the regulation of BH3 only proteins by ERK1/2 signalling. In fact he enjoyed his time in the Cook laboratory so much that in 2013 he decided to stay on for a post-doc as part of a collaboration with AstraZeneca and Duncan Jodrell’s laboratory at the Cambridge Cancer Research Institute. He is investigating the mechanisms that confer intrinsic resistance to MEK1/2 inhibitors in pancreatic cancer and other tumour types, and how to improve their efficacy through combination therapies. Matt’s interests include travelling, playing football and tennis, and watching sport. In keeping with the latter he follows the fortunes of Southampton FC.

Latest Publications

RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence.

Galloway A, Saveliev A, Łukasiak S

Science (New York, N.Y.)
352 1095-9203:453-9 (2016)

PMID: 27102483

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.

Lochhead PA, Clark J, Wang LZ

Cell cycle (Georgetown, Tex.)
15 1551-4005:506-18 (2016)

PMID: 26959608

Maternal DNA Methylation Regulates Early Trophoblast Development.

Branco MR, King M, Perez-Garcia V

Developmental cell
36 1878-1551:152-63 (2016)

PMID: 26812015

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.

Caunt CJ, Sale MJ, Smith PD

Nature reviews. Cancer
15 1474-1768:577-92 (2015)

PMID: 26399658

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.

Ashford AL, Dunkley TP, Cockerill M

Cellular and molecular life sciences : CMLS
1420-9071: (2015)

PMID: 26346493

Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer.

Sale MJ, Cook SJ

Biochemical Society transactions
42 1470-8752:776-83 (2014)

PMID: 25109957